View our masking and visitation guidelines based on current rates of respiratory illnesses in the community.

Our new building on the hospital campus, Forest B, is open. Families and visitors can park in the new Forest B garage next to Emergency.

Clinical Trial Search block Test

SC-4020 VITAS: Atezolizumab in combination with chemotherapy for pediatric relapsed/refractory solid tumors: An open-label, phase I/II, single-arm, multi-center trial

SC-4020 VITAS

Condition(s): Soft Tissue
Phase: II
Clinicaltrials.gov ID: NCT04796012

What is the goal of the study?

Determine the feasibility of administering vincristine, irinotecan, temozolomide, and atezolizumab simultaneously in children with relapsed or refractory solid tumors. Determine the objective response rate (ORR) of children with PD L1(+) relapsed or refractory rhabdomyosarcoma treated with vincristine, irinotecan, temozolomide, and atezolizumab.

Who can participate in the study?

Everyone

Study Team:

PI (Study Doctor): Catherine Albert
Study Team Member: HemOnc CRAs, hemonccras@seattlechildrens.org